**Core tip:** As a supplement to recent guidelines, this manuscript demonstrates that lymphocyte-to-monocyte ratio could effectively differentiates the survival outcome between self-expanding metal stenting and emergency surgery in patients with obstructive colon cancer. Self-expanding metal stents might be preferred to the "potential benefit group" that with a low preoperative lymphocyte-to-monocyte ratio (\<1.67).

INTRODUCTION
============

Although several studies have been implemented in the screening for colorectal cancer, approximately 8%-29% of patients are diagnosed with obstructive colorectal cancer (OCC) as the first symptom\[[@B1],[@B2]\]. Emergency surgery (ES) with or without stoma construction and self-expandable metal stent (SEMS) insertion as a bridge to surgery (BTS) are the current methods for OCC\[[@B3]\]. A BTS is preferred for symptomatic OCC due to effective decompression, better preoperative nutritional preparation, an improvement in the immunological reaction, and a lower incidence of stoma creation\[[@B4],[@B5]\]. However, the enhancement of tumor dissemination and early recurrence reported by some studies hinder the usage of a self-expandable metal stent in OCC\[[@B6],[@B7]\]. Despite this, there is still no common consensus. Several predictive models on the prognostic outcome of OCC, including ASA, age, Duck's stage, and prognostic nutritional index, have been established\[[@B8],[@B9]\], but few focus on the inflammation index\[[@B10]\].

The inflammatory response plays a dual role in the development of a tumor. On one hand, a chronic inflammatory response triggers the local accumulation of monocytes, platelets, and neutrophils, which secrete cytokines and inflammatory factors to induce tumor angiogenesis and metastasis. On the other hand, increasing monocytes and lymphatic cells would enhance the resistance against tumor invasion\[[@B11]\]. Increasing evidence shows that an elevated neutrophil-to-lymphocyte ratio (NLR) is closely related to a poor prognosis in ovarian cancer, cholangiocarcinoma, and elective colorectal cancer (CRC)\[[@B12]-[@B14]\]. The overexpression of circulating derived NLR, an effective biomarker for the diagnosis of early pancreatic cancer\[[@B15]\], was accompanied by increasing distal organ invasion in metastatic CRC\[[@B16]\]. An elevated preoperative lymphocyte-to-monocyte ratio (LMR), as a superior existing biomarker, was positively correlated with the survival outcomes of patients with resectable CRC and presented better overall survival\[[@B17]\]. Other inflammatory indexes, such as the platelet-to-lymphocyte ratio (PLR)\[[@B14]\] and systemic immune inflammation index (SII)\[[@B18]\], have also been studied in the exploration of optimal predictive models for tumor recurrence.

Different from the acute inflammatory response in patients undergoing ES, the alleviation of bowel obstruction after successful SEMS insertion in patients undergoing BTS would elicit a better immunological reaction and nutritional support, which might change the predictive factors for prognosis between the two groups. Preoperative inflammation indexes might favor patient selection and the establishment of a valid predictive model for the prognosis of OCC. In this study, we compared different inflammation indexes and other clinicopathological factors to evaluate the potential indications for ES and BTS for OCC.

MATERIALS AND METHODS
=====================

Patient population
------------------

All patients (*n =* 128) who underwent surgery for OCC at the Department of Emergency Surgery of Fujian Medical University Union Hospital from January 2008 to October 2015 were included in this study. Data from the patients' records were retrospectively collected and evaluated. The Institutional Review Board of Fujian Medical Union Hospital approved the study protocol. All patients provided informed consent for surgery. Patients were divided into an ES group and a BTS group based on the grade of bowel obstruction and families' choices. For incomplete obstruction, ES was preferred as the first choice. For complete obstruction, once patients who refused to accept SEMS insertion or failed in SEMS insertion, they would accept ES with intraoperative decompression.

Classification criteria
-----------------------

Patients who manifested with bowel obstruction were enrolled in this study. All diagnoses of OCC were confirmed by both emergency abdominal computed tomography (CT) and a pathological examination. The exclusion criteria were as follows: (1) Patients who rejected surgery or were diagnosed with acute peritonitis or perforation; (2) Patients with severe infection, hematological diseases, or an immunological deficit; and (3) Patients who received preoperative adjuvant chemotherapy, radiotherapy, or immunotherapy.

Surgical protocols
------------------

For left-side OCC, we performed intraoperative lavage or manual decompression for better bowel preparation, and these protocols have been previously depicted. For right-side OCC, radical dissection with one-stage anastomosis was performed\[[@B19]\].

SEMS with BTS
-------------

Stent insertion was performed by an endoscopist who had experienced over 400 endoscopic retrograde cholangiopancreatography (ERCP) procedures. Bridge to elective surgery was performed, once the stent was so successfully inserted that the intestinal obstruction completely relieved. Otherwise, ES was immediately performed.

Definition of variants
----------------------

The neutrophil, lymphocyte, monocyte, and platelet counts from the peripheral blood tests and the inflammation indexes dependent on these factors were performed before surgery (*e.g*., NLR, dNLR, LMR, PLR, and SII) and stent insertion (*e.g*., NLR-pre, dNLR-pre, LMR-pre, PLR-pre, and SII-pre). The methods for the calculation of NLR, dNLR, LMR, and PLR have been described in previous studies\[[@B13]\]. The SII was calculated as (platelet count × neutrophil count)/lymphocyte count\[[@B18]\]. The cutoff point and the area under the curve (AUC) value of each inflammation index for the prediction of OS and DFS were determined with X-tile 3.6.1 software (Yale University, New Haven, CT, United States)\[[@B20]\]. According to the cutoff point, patients were divided into low-ratio and high-ratio groups for further analysis.

According to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual (7th edition)\[[@B21]\], we classified the tumor pathological stage. Comorbidities were defined as hypertension, diabetes mellitus, and single and multiple organ dysfunction. The degree of obstructive symptoms was divided into five grades, termed as The ColoRectal Obstruction Scoring System (CROSS)\[[@B22]\]. According to the Clavien-Dindo classification system\[[@B23],[@B24]\], we classified the perioperative complications into five grades.

Statistical analysis
--------------------

Qualitative variables were compared by the *χ*^2^ test or Fisher's exact test, and quantitative variables were compared *via t*-tests. Through Kaplan-Meier analysis, the 3-year OS and 3-year DFS were calculated. A Cox proportional hazards regression model was built to identify the independent risk factors for 3-year DFS and 3-year OS. Stratification analysis was used to compare the differences between subgroups. All *P*-values less than 0.05 were considered statistically significant. All statistical analyses and graphs were generated using SPSS 23.0 software.

RESULTS
=======

Baseline characteristics
------------------------

There were 128 patients enrolled in this study, who were divided into an ES group (*n* = 90) and a BTS group (*n* = 38), with similar age and sex ratios between the groups (*P \>* 0.05). The average tumor size was 6.88 ± 2.68 cm in the BTS group, with a higher proportion of tumors located on the left side of the colon (73.70% *vs* 41.10%, *P* = 0.005), and was much larger than the tumor size in the ES group (5.76 ± 2.12 cm, *P* = 0.015). Moreover, the obstructive symptoms were more severe in the BTS group than in the ES group (Grade 0-I, 97.40% *vs* 68.50%, *P =* 0.001), as presented in Table [1](#T1){ref-type="table"}. The remaining characteristic factors, including BMI, abdominal surgery history, comorbidities, ASA grade, pTNM stage, histological features, and the ratio of chemotherapy were similar between the ES and BTS groups (*P \>* 0.05).

###### 

Comparison of clinicopathological characteristics between emergency surgery and bridge to surgery groups

  **Characteristic**           **ES group (*n =* 90)**   **BTS group (*n =* 38)**   ***P*-value**
  ---------------------------- ------------------------- -------------------------- ---------------
  Age (yr)                     61.58 ± 14.84             63.21 ± 13.55              0.561
  Female/Male, (%)             31 (34.40)/59 (65.60)     15 (39.50)/23 (60.50)      0.588
  Size, (cm)                   5.76 ± 2.12               6.88 ± 2.68                **0.015**
  BMI, (kg/m^2^)               21.76 ± 2.42              22.20 ± 3.20               0.411
  Cross score, (%)                                                                  **0.001**
  0                            21 (23.60)                21 (55.30)                 
  1                            40 (44.90)                16 (42.10)                 
  2                            17 (19.10)                1 (2.60)                   
  3                            10 (11.20)                0 (0.00)                   
  4                            1 (0.80)                  0 (0.00)                   
  ASH (+)/(-), (%)             17 (18.90)/73 (81.10)     10 (26.30)/28 (73.70)      0.347
  Comorbidities (+)/(-), (%)   37 (41.10)/53 (58.90)     21 (55.30)/17 (44.70)      0.142
  ASA grade, (%)                                                                    0.299
  I                            2 (2.20)                  3 (7.90)                   
  II                           63 (70.00)                28 (73.70)                 
  ≥III                         25 (27.80)                7 (18.40)                  
  Location, (%)                                                                     **0.005**
  Right-side colon             13 (14.40)                1 (2.60)                   
  Transverse colon             30 (33.30)                5 (13.20)                  
  Left-side colon              37 (41.10)                28 (73.70)                 
  Rectum                       10 (11.10)                4 (10.50)                  
  pTNM stage, (%)                                                                   0.186
  I                            4 (4.40)                  0 (0.00)                   
  II                           23 (25.60)                9 (23.70)                  
  III                          44 (48.90)                25 (65.80)                 
  IV                           19 (21.10)                4 (10.50)                  
  T stage, (%)                                                                      0.186
  T1                           4 (4.40)                  0 (0.00)                   
  T2                           23 (25.60)                9 (23.70)                  
  T3                           44 (48.90)                25 (65.80)                 
  T4                           19 (21.10)                4 (10.50)                  
  N stage, (%)                                                                      0.471
  N0                           31 (34.40)                9 (23.70)                  
  N1                           35 (38.90)                18 (47.40)                 
  N2                           24 (26.70)                11 (28.90)                 
  M stage, (%)                                                                      0.292
  M0                           71 (78.9)                 33 (86.8)                  
  M1                           19 (21.1)                 5 (13.2)                   
  Histological features, (%)                                                        0.308
  Well differentiated          3 (2.30)                  0 (0.00)                   
  Moderately differentiated    61 (67.80)                30 (78.90)                 
  Poorly differentiated        26 (28.90)                8 (21.10)                  
  LVI (+)/(-), (%)             15 (16.70)/75 (83.30)     14(36.80)/24(63.20)        **0.013**
  WBC, (10^\^^9)               8.99 ± 5.10               7.57 ± 2.61                **0.042**
  NLR, (ratio)                 7.11 ± 6.72               4.88 ± 3.02                **0.012**
  dNLR, (ratio)                1.66 ± 0.41               1.67 ± 0.27                0.756
  PLR, (ratio)                 245.61 ± 144.17           229.98 ± 122.38            0.562
  LMR, (ratio)                 2.84 ± 2.43               2.34 ± 1.19                0.127
  SII, (ratio)                 1969.03 ± 2316.10         1235.74 ± 849.53           **0.011**
  WBC-pre, (10^\^^9)           9.18 ± 5.13               8.56 ± 3.44                0.434
  NLR-pre, (ratio)             7.62 ± 6.97               6.05 ± 3.03                0.084
  dNLR-pre, (ratio)            1.65 ± 0.41               1.68 ± 0.45                0.652
  PLR-pre, (ratio)             263.98 ± 161.96           270.89 ± 171.35            0.830
  LMR-pre, (ratio)             2.77 ± 2.32               2.38 ± 1.66                0.354
  SII-pre, (ratio)             2186.46 ± 2474.96         1712.60 ± 1157.32          0.149
  CEA, (ng/mL)                 30.19 ± 120.54            17.88 ± 27.47              0.541
  Chemotherapy (+)/(-), (%)    62 (68.90)/28 (31.10)     20 (52.60)/18 (47.40)      0.080

SEMS: Self-expanding metal stents; BTS: Bridge to surgery; ASH: Abdominal surgery history; WBC: White blood cells; dNLR: Derived neutrophil--to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune inflammation index; LMR: Lymphocyte-to-monocyte ratio; Cross: Colorectal obstruction scoring system; LVI: Lymphovascular invasion. *P* \< 0.05 was considered statistically significant.

Outcome comparison between the ES and BTS groups
------------------------------------------------

The blood loss in the BTS group was lower than that in the ES group (133.68 ± 95.76 mL *vs* 177.30 ± 134.37 mL, *P* = 0.072), with similar gastrointestinal recovery and postoperative complications (*P* \> 0.05) (Table [2](#T2){ref-type="table"}). Analogical survival outcomes including 3-year OS (30.10 ± 9.64 mo *vs* 29.41 ± 11.33 mo, *P* = 0.732) and 3-year DFS (27.59 ± 12.19 mo *vs* 27.48 12.17 mo, *P =* 0.969) were compared between the ES and BTS groups, and are plotted in Figure [1](#F1){ref-type="fig"}.

![Long-term survival analysis between emergency surgery and bridge to surgery groups. Disease-free survival (DFS, A) and overall survival (OS, B) after surgery seemed similar between the bridge to surgery (BTS) and emergency surgery (ES) groups.](WJG-25-4970-g001){#F1}

###### 

Comparison of short-term and long-term outcomes between emergency surgery and bridge to surgery groups

  **Characteristic**                  **ES group (*n =* 90)**   **BTS group (*n =* 38)**   ***P*-value**
  ----------------------------------- ------------------------- -------------------------- ---------------
  Surgical time, (min)                217.89 ± 60.69            204.64 ± 66.13             0.275
  Blood loss, (mL)                    177.30 ± 134.37           133.68 ± 95.76             **0.072**
  Number of LNs                       19.51 ± 9.47              21.45 ± 8.29               0.276
  Time to flatus, (d)                 3.88 ± 1.65               3.61 ± 1.15                0.359
  Time to semi-fluid, (d)             8.62 ± 3.22               8.64 ± 3.96                0.738
  Total hospital-stay, (d)            22.17 ± 12.48             22.34 ± 7.78               0.936
  Stoma construction, *n* (%)         20 (22.20)                8 (21.10)                  0.884
  CD classification system, *n* (%)                                                        0.547
  Grade I                             0 (0.00)                  2 (2.20)                   
  Grade II                            44 (48.90)                16 (42.10)                 
  Grade III                           13 (14.40)                5 (13.20)                  
  Grade IV                            9 (10.00)                 2 (5.30)                   
  Grade V                             1 (2.60)                  1 (1.10)                   
  Pneumonia, *n* (%)                  18 (20.00)                8 (21.10)                  0.892
  Incision infection, *n* (%)         16 (17.80)                5 (13.20)                  0.519
  ICU intervention, *n* (%)           8 (8.90)                  1 (2.60)                   0.192
  Leakage, *n* (%)                    3 (3.30)                  1 (2.60)                   0.658
  Sepsis, *n* (%)                     3 (3.30)                  1 (2.60)                   0.658
  SAE, *n* (%)                        23 (25.60)                8 (21.10)                  0.587
  30 d-mortality, *n* (%)             1 (1.10)                  1 (2.60)                   0.507
  36-OS time, (mo)                    30.10 ± 9.64              29.41 ± 11.33              0.732
  36-DFS time, (mo)                   27.59 ± 12.19             27.48 ± 12.17              0.969

LN: Lymph node; SEMS: Self-expanding metal stents; BTS: Bridge to surgery; SAE: Severe adverse effects. *P* \< 0.05 was considered statistically significant.

Predictive values and cutoff points of different inflammation indexes
---------------------------------------------------------------------

A decreasing tendency was observed for WBC (8.56 × 10^9^ ± 3.44 × 10^9^), NLR (4.88 ± 3.02), and SII (1235.74 ± 849.53) in the BTS group after SEMS insertion, compared with the WBC (7.57 × 10^9^ ± 2.61 × 10^9^), NLR (6.05 ± 3.03), and SII (1712.60 ± 1157. 32) before SEMS insertion (*P* \< 0.05), as presented in Table [1](#T1){ref-type="table"}. Different inflammation indexes were analyzed between the ES and BTS groups. As a result, dNLR was preferred as a prognostic biomarker for the ES group since it had the highest AUC for 3-year OS (0.679, 95%CI: 0.551-0.808) and 3-year DFS (0.679, 95%CI: 0.551-0.808); the cutoff point value was 1.57. Conversely, based on the highest AUC for 3-year OS (0.611, 95%CI: 0.424-0.798) and 3-year DFS (0.571, 95%CI: 0.366-0.776), the LMR was recommended as a prognostic biomarker for the BTS group, with 1.67 as its cutoff point. These data are depicted in Table [3](#T3){ref-type="table"} and plotted in Figure [2](#F2){ref-type="fig"}.

![Receiver operating characteristic curve and long-term survival analysis of emergency surgery and bridge to surgery group. Derived neutrophil-to-lymphocyte ratio (dNLR) is preferred as a prognostic biomarker for the emergency surgery (ES) group with the highest area under receiver operating characteristic curve (AUC) for 3-year overall survival (OS) (0.679, 95%CI: 0.551-0.808) (A) and 3-year disease-free survival (DFS) (0.679, 95%CI: 0.551-0.808) (B), with a cutoff point value of 1.57. High-ratio grade of dNLR (≥1.57) was closely related to lower 3-year DFS (≥1.57 *vs* \<1.57, 23.10 ± 13.85 mo *vs* 31.45 ± 9.35 mo, *P =* 0.009) in the ES group (D), but not with 3-year OS (C). Lymphocyte-to-monocyte ratio (LMR) was preferred as a prognostic biomarker for bridge to surgery (BTS) group with the highest AUC for 3-year OS (0.611, 95%CI: 0.424-0.798) (E) and 3-year DFS (0.571, 95%CI: 0.366-0.776) (F), with a cutoff point value of 1.67. High-ratio grade of LMR (≥1.67) was closely related to lower 3-year OS (≥1.67 *vs* \<1.67, 23.10 ± 13.85 mo *vs* 33.78 ± 5.35 mo, *P =* 0.020) (G) and 3-year DFS (≥ 1.67 *vs* \< 1.67, 22.67 ± 14.02 mo *vs* 31.50 ± 8.89 mo, *P =* 0.046) in the BTS group (H).](WJG-25-4970-g002){#F2}

###### 

Receiver operating characteristic curve analysis of long-term survival of emergency surgery and bridge to surgery groups

  **Group**   **Characteristic**   **3-year OS**   **3-year DFS**                                
  ----------- -------------------- --------------- ---------------- ------------- ------ ------- -------------
  ES          NLR                  19.3            0.582            0.446-0.718   19.3   0.565   0.407-0.723
              dNLR                 2.02            0.679            0.551-0.808   1.57   0.696   0.554-0.837
              PLR                  155             0.550            0.414-0.686   317    0.549   0.392-0.707
              SII                  3645            0.587            0.454-0.721   3645   0.564   0.403-0.726
              CEA                  6.7             0.591            0.458-0.724   11.2   0.604   0.442-0.766
  BTS         LMR                  1.67            0.611            0.424-0.798   1.67   0.571   0.366-0.776
              CEA                  7.6             0.549            0.350-0.747   5.5    0.552   0.348-0.756

SEMS: Self-expanding metal stents; BTS: Bridge to surgery; AUC: Area under the receiver operating characteristic curve; dNLR: Derived neutrophil-to-lymphocyte ratio; PLR: Platelet--to-lymphocyte ratio; SII: Systemic immune inflammation index; LMR: Lymphocyte-to-monocyte ratio; CEA: Carcino-embryonic antigen. *P* \< 0.05 was considered statistically significant.

Clinical evaluation of different inflammation indexes
-----------------------------------------------------

In Table [4](#T4){ref-type="table"}, patients were divided into high-ratio and low-ratio grades based on the dNLR in the ES group and the LMR in the BTS group. A high-ratio grade of dNLR (≥ 1.57) was closely related to a higher proportion of tumors located on the left side of the colon and rectum (*P* = 0.007), and a higher incidence of stoma construction (*P =* 0.001) and postoperative pneumonia (*P =* 0.054), with a lower 3-year DFS (dNLR ≥ 1.57: 23.10 ± 13.85 mo *vs* dNLR \< 1.57: 31.45 ± 9.35 mo, *P =* 0.009) in the ES group. Separately, a high-ratio grade of the LMR (≥ 1.67) in the BTS group showed more advanced lymphovascular metastasis (*P* = 0.072) and lymph node invasion (*P* = 0.009), with a lower 3-year OS (LMR ≥ 1.67: 25.26 ± 13.88 mo *vs* LMR \< 1.67: 33.78 ± 5.35 mo, *P =* 0.020) and 3-year DFS (LMR ≥ 1.67: 22.67 ± 14.02 mo *vs* LMR \< 1.67: 31.50 ± 8.89 mo, *P =* 0.046). The dNLR was the only independent risk factor in the ES group both for 3-year OS (HR = 2.34, 95%CI: 1.08-5.07, *P =* 0.032) and 3-year DFS (HR = 3.02, 95%CI: 1.23-7.42, *P =* 0.016). In contrast, the status of LVI (HR = 3.52, 95%CI: 1.03-12.02, *P =* 0.045) and the LMR (HR = 4.57, 95%CI: 0.98-21.38, *P =* 0.053) significantly affected the 3-year OS in the BTS group. Only the LMR was an independent risk factor for 3-year DFS (HR = 3.11, 95%CI: 1.13-8.54, *P =* 0.052) in the BTS group, as shown in Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"} and Figure [2](#F2){ref-type="fig"}.

###### 

Comparison of clinicopathological features between high-ratio and low-ratio grades in both emergency surgery and bridge to surgery groups

  **Characteristic**                 **ES group (*n =* 86)**   **BTS group (*n =* 38)**                                                           
  ---------------------------------- ------------------------- -------------------------- ----------- --------------------- --------------------- -----------
  Cross score, (%)                                                                        0.738                                                   0.378
  0                                  11 (27.5)                 10 (21.7)                              10 (50.0)             11 (61.1)             
  1                                  16 (40.0)                 22 (47.8)                              10 (50.0)             6 (33.3)              
  2                                  8 (20.0)                  8 (17.4)                               0 (0.0)               1 (5.6)               
  3                                  4 (10.0)                  6 (13.0)                                                                           
  4                                  1 (2.5)                   0 (0.0)                                                                            
  ASH (+)/(-), (%)                   6 (15.0)/34 (85.0)        10 (21.7)/36 (78.3)                    4 (20.0)/16 (80.0)    6 (33.3)/12 (66.7)    
  Comorbidities (+)/(-), (%)         20 (50.0)/20 (50.0)       17 (37.0)/29 (63.0)                    9 (45.0)/11 (55.0)    12 (66.7/)/6 (33.3)   
  ASA grade, (%)                                                                          0.320                                                   0.623
  I                                  0 (0.0)                   1 (1.6)                                1 (5.0)               2 (11.1)              
  II                                 13 (56.5)                 47 (74.6)                              16 (80.0)             12 (66.7)             
  ≥III                               10 (43.5)                 15 (23.8)                              3 (15.0)              4 (22.2)              
  Location, (%)                                                                           **0.007**                                               0.523
  Right-side colon                   2 (5.0)                   11 (23.9)                              1 (5.0)               0 (0.00)              
  Transverse colon                   10 (25.0)                 19 (41.3)                              3 (15.0)              2 (11.1)              
  Left-side colon                    21 (52.5)                 13 (28.3)                              13 (65.0)             15 (83.3)             
  Rectum                             7 (17.5)                  3 (6.5)                                3 (15.0)              1 (5.6)               
  pTNM stage, (%)                                                                         0.141                                                   0.592
  I                                  0 (0.0)                   4 (8.7)                                \-                    \-                    
  II                                 12 (30.0)                 10 (21.7)                              4 (20.0)              5 (27.8)              
  III                                17 (42.5)                 24 (52.2)                              13 (65.0)             12 (66.7)             
  IV                                 11 (27.5)                 8 (17.4)                               3 (15.0)              1 (5.6)               
  T stage, (%)                                                                            0.141                                                   0.592
  T1                                 0 (0.0)                   4 (8.7)                                \-                    \-                    
  T2                                 12 (30.0)                 10 (21.7)                              4 (20.0)              5 (27.8)              
  T3                                 17 (42.5)                 24 (52.2)                              13 (65.0)             12 (66.7)             
  T4                                 11 (27.5)                 8 (17.4)                               3 (15.0)              1 (5.6)               
  N stage, (%)                                                                            0.648                                                   **0.009**
  N0                                 16 (40.0)                 14 (30.4)                              4 (20.0)              5 (27.8)              
  N1                                 14 (35.0)                 19 (41.3)                              6 (30.0)              12 (66.7)             
  N2                                 10 (25.0)                 13 (28.3)                              10 (50.0)             1 (5.6)               
  M stage, (%)                                                                            0.260                                                   0.552
  M0                                 29 (72.5)                 38 (82.6)                              17 (85.0)             16 (88.9)             
  M1                                 11 (27.5)                 8 (17.4)                               3 (15.0)              2 (11.1)              
  Histological features, (%)                                                              0.605                                                   0.411
  Well differentiated                1 (2.5)                   2 (4.3)                                \-                    \-                    
  Moderately differentiated          30 (75.0)                 30 (65.2)                              15 (75.0)             15 (83.3)             
  Poorly differentiated              9 (22.5)                  14 (30.4)                              5 (25.0)              3 (16.7)              
  LVI (+)/(-), (%)                   9 (22.5)/31 (77.5)        6 (13.0)/40 (87.0)         0.249       10 (50.0)/10 (50.0)   4 (22.2)/14 (77.8)    **0.076**
  Stoma construction, (%)                                                                 **0.000**                                               0.589
  Stoma                              17 (42.5)                 3 (6.5)                                4 (20.0)              4 (22.2)              
  None                               23(57.5)                  43 (93.5)                              16 (80.0)             14 (77.8)             
  Pneumonia, (+)/(-), (%)            12 (30.0)/28 (70.0)       6 (13.0)/40 (87.0)         **0.054**   2 (10.0)/18(90.0)     6 (33.3)/12 (66.7)    0.086
  Incision infection, (+)/(-), (%)   8 (20.0)/32 (80.0)        8 (17.4)/38 (82.6)         0.486       2 (10.0)/18 (90.0)    3 (16.7)/15 (83.3)    0.448
  ICU intervention, (+)/(-), (%)     5 (12.5)/35 (87.5)        3 (6.5)/43 (93.5)          0.281       1 (5.0)/19 (95.0)     0 (0.0)/18 (100.0)    0.526
  Leakage, (+)/(-), (%)              1 (2.5)/39 (97.5)         2 (4.3)/44 (95.7)          0.553       0 (0.0)/20 (100.0)    1 (5.6)/17 (94.4)     0.474
  Sepsis, (+)/(-), (%)               1 (2.5)/39 (97.5)         2 (4.3)/44 (95.7)          0.553       0 (0.0)/20 (100.0)    1 (5.6)/17 (94.4)     0.474
  SAE, (+)/(-), (%)                  10 (25.0)/30 (75.0)       11 (23.9)/35 (76.1)        0.907       5 (25.0)/15 (75.0)    3 (16.7)/15 (83.3)    0.411
  30-day mortality, *n* (%)          1 (2.5)/39 (97.5)         0 (0.0)/46 (100.0)         0.465       1 (5.0)/19 (95.0)     0 (0.0)/18 (100.0)    0.526
  36-OS time, (months)               28.05 ± 10.28             31.61 ± 9.16               0.106       25.26 ± 13.88         33.78 ± 5.35          0.020
  36-DFS time, (months)              23.10 ± 13.85             31.45 ± 9.35               0.009       22.67 ± 14.02         31.50 ± 8.89          0.046

SEMS: Self-expanding metal stents; BTS: Bridge to surgery; Cross: Colorectal obstruction scoring system; ASH: Abdominal surgery history; dNLR: Derived neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune inflammation index; LMR: Lymphocyte-to-monocyte ratio; LVI: Lymphovascular invasion; OS: Overall survival; DFS: Disease-free survival; ICU: Intense care unit; SAE: Severe adverse effects. *P* \< 0.05 was considered statistically significant.

###### 

Univariate and multivariate analyses of risk factors for survival outcomes in both emergency surgery and bridge to surgery groups

  **3-year overall survival**           **ES group (*n =* 90)**   **BTS group (*n =* 38)**                                                                                      
  ------------------------------------- ------------------------- -------------------------- ------------------ ----------- ------------------- ----------- ------------------- -----------
  Characteristic                        HR (95%CI)                *P*-value                  HR (95%CI)         *P*-value   HR (95%CI)          *P*-value   HR (95%CI)          *P*-value
  CEA (≥5 ng/mL *vs* \<5 ng/mL)         1.48 (0.70-3.11)          0.303                                                     2.53 (0.68-9.35)    0.165                           
  ASA (Grade ≥ III *vs* Grade \< III)   1.50 (0.72-3.11)          0.277                                                     1.64 (0.45-5.96)    0.454                           
  pT stage (pT3-4 *vs* pT1-2)           1.66 (0.72-3.83)          0.238                                                     4.17 (1.09-15.95)   **0.037**                       
  pN stage (pN+ *vs* pN0)               1.05 (0.51-2.19)          0.887                                                     5.02 (0.65-38.66)   0.122                           
  LVI (+) *vs* LVI (-)                  1.30 (0.53-3.15)          0.568                                                     3.78 (1.23-11.64)   **0.020**   3.52 (1.03-12.02)   **0.045**
  NLR ≥ 19.3 *vs* NLR \< 19.3           2.98 (1.27-6.97)          **0.012**                                                                                                     
  dNLR ≥ 1.57 *vs* dNLR \< 1.57         2.40 (1.12-5.13)          **0.024**                  2.34 (1.08-5.07)   **0.032**                                                       
  PLR ≥ 155 *vs* PLR \< 155             1.83 (0.70-4.79)          0.217                                                                                                         
  SII ≥ 3645 *vs* SII \< 3645           1.61 (0.71-3.61)          0.252                                                                                                         
  LMR ≥ 1.67 *vs* LMR \< 1.67                                                                                               4.09 (1.12-14.87)   **0.033**   4.57 (0.98-21.38)   **0.053**
  Chemotherapy (+) *vs* (-)             0.74 (0.36-1.51)          0.402                                                     1.43 (0.47-4.38)    0.529                           

SEMS: Self-expanding metal stents; BTS: Bridge to surgery; dNLR: Derived neutrophil-to-lymphocyte ratio; PLR: Platelet--to-lymphocyte ratio; SII: Systemic immune inflammation index; LMR: Lymphocyte-to-monocyte ratio; LVI: Lymphovascular invasion. *P* \< 0.05 was considered significant.

###### 

Univariate and multivariate analyses of risk factors for oncological outcomes in both emergency surgery and bridge to surgery groups

  **3-year disease-free survival**      **ES group (*n =* 56)**   **BTS group (*n =* 32)**                                                                                    
  ------------------------------------- ------------------------- -------------------------- ----------------- ----------- ------------------- ----------- ------------------ -----------
  Characteristic                        HR (95%CI)                *P*-value                  HR (95%CI)        *P*-value   HR (95%CI)          *P*-value   HR (95%CI)         *P*-value
  CEA (≥ 5 ng/mL *vs* \<5 ng/mL)        1.71 (0.74-3.95)          0.209                                                    2.67 (0.72-9.90)    0.141                          
  ASA (Grade ≥ III *vs* Grade \< III)   0.890 (0.36-2.23)         0.803                                                    1.49 (0.41-5.43)    0.542                          
  pT stage (pT3-4 *vs* pT1-2)           2.26 (0.85-6.02)          0.104                                                    2.48 (0.55-11.18)   0.239                          
  pN stage (pN+ *vs* pN0)               1.48 (0.64-3.43)          0.361                                                    2.48 (0.55-11.18)   0.239                          
  LVI (+) *vs* LVI (-)                  2.92 (1.25-6.81)          **0.013**                                                1.97 (0.66-5.88)    0.224                          
  NLR ≥ 19.3 *vs* NLR \< 19.3           2.76 (1.02-7.45)          **0.046**                                                                                                   
  dNLR ≥ 1.57 *vs* dNLR \< 1.57         2.85 (1.17-6.95)          **0.021**                  3.02(1.23-7.42)   **0.016**                                                      
  PLR ≥ 317 *vs* PLR \< 317             1.55 (0.66-3.67)          0.314                                                                                                       
  SII ≥ 3645 *vs* SII \< 3645           2.04 (0.86-4.83)          0.104                                                                                                       
  LMR ≥ 1.67 *vs* LMR \< 1.67                                                                                              2.54 (0.83-7.80)    0.091       3.11 (1.13-8.54)   **0.052**
  Chemotherapy (+) *vs* (-)             0.95 (0.41-2.19)          0.896                                                    1.44 (0.47-4.41)    0.523                          

SEMS: Self-expanding metal stents; BTS: Bridge to surgery; dNLR: Derived neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune inflammation index; LMR: Lymphocyte-to-monocyte ratio; LVI: Lymphovascular invasion. Chemotherapy (+), accept chemotherapy lately. Chemotherapy (-), refuse to chemotherapy lately. *P* \< 0.05 was considered significant.

Selective choices based on inflammatory biomarkers
--------------------------------------------------

By stratification analysis of 3-year OS and 3-year DFS in different grades of dNLR and LMR, we revealed that only the LMR obviously differentiated the oncological and survival outcomes between the ES and BTS groups. A lower LMR (\<1.67), as a protective factor, indicated a lower rate of death (HR = 0.40, 95%CI: 0.18-0.92, *P =* 0.031) and tumor recurrence (HR = 0.42, 95%CI: 0.17-1.07, *P =* 0.068) in the BTS group. Conversely, a higher LMR (≥1.67), as a risk factor, showed a higher proportion of death (HR = 4.32, 95%CI: 1.27-14.82, *P =* 0.019) and tumor recurrence (HR = 2.72, 95%CI: 0.97-7.65, *P =* 0.058) in the BTS group; these data are presented in Table [7](#T7){ref-type="table"} and Figure [3](#F3){ref-type="fig"}.

![Analysis of 3-year overall survival and 3-year disease-free survival, by different lymphocyte-to-monocyte ratios between emergency surgery and bridge to surgery groups. *P \<* 0.05 (log-rank test). Low lymphocyte-to-monocyte ratio (LMR) (LMR \< 1.67) indicated higher rates of 3-year OS (A) (HR = 0.40, 95%CI: 0.18-0.92, *P =* 0.031) and 3-year disease-free survival (DFS) (C) (HR = 0.42, 95%CI: 0.17-1.07, *P =* 0.068) in the bridge to surgery (BTS) group. Conversely, high LMR (LMR ≥ 1.67) showed lower proportions of 3-year OS (B) (HR = 4.32, 95%CI: 1.27-14.82, *P =* 0.019) and 3-year DFS (d) (HR = 2.72, 95%CI: 0.97-7.65, *P =* 0.058) in the BTS group.](WJG-25-4970-g003){#F3}

###### 

Stratification analysis of oncological and survival outcomes between high-ratio and low-ratio grades in both emergency surgery and bridge to surgery groups

  **Characteristic**   **3-year OS**       **3-year DFS**                      
  -------------------- ------------------- ---------------- ------------------ -------
  ES (dNLR \< 1.57)    Reference           \-               Reference          \-
  BTS (dNLR \< 1.57)   0.51 (0.18-1.39)    0.185            0.42 (0.13-1.34)   0.144
  ES (dNLR ≥ 1.57)     Reference           \-               Reference          \-
  BTS (dNLR ≥ 1.57)    1.87 (0.79-4.43)    0.155            1.79 (0.77-4.20)   0.178
  ES (LMR \< 1.67)     Reference           \-               Reference          \-
  BTS (LMR \< 1.67)    4.34 (1.27-14.82)   0.019            2.72 (0.97-7.65)   0.058
  ES (LMR ≥ 1.67)      Reference           \-               Reference          \-
  BTS (LMR ≥ 1.67)     0.40 (0.18-0.92)    0.031            0.42 (0.17-1.07)   0.068

SEMS: Self-expanding metal stents; BTS: Bridge to surgery; dNLR: Derived neutrophil-to-lymphocyte ratio; LMR: Lymphocyte-to-monocyte ratio. *P* \< 0.05 was considered statistically significant.

DISCUSSION
==========

OCC is always accompanied by a severe local and systemic inflammatory response; some reasons, including the overgrowth of intestinal bacteria, their translocation through the distended colonic wall, and, moreover, septic shock, have been recognized. In this study, we found that the cutoff point for the NLR of 19.30 was much higher than that in elective CRC\[[@B14],[@B24]\], supporting the existing severe systemic inflammation. Although ES and BTS *via* SEMS insertion have been widely performed, there is still not an objective indication for either. Weighing the balance between oncological outcomes and better preoperative nutritional support with the alleviation of systemic inflammation, BTS *via* SEMS insertion is only recommended for symptomatic and high surgical risk groups, especially left-side OCC, by the ESGE and World Society of Emergency Surgery (WSES)\[[@B1],[@B3]\]. In this study, analogous with a previous study\[[@B25]\], the BTS group had a higher proportion of LVI (36.80%), though similar 3-year OS and 3-year DFS were observed between the ES and BTS groups. A decreasing tendency in the WBC, NLR, and SII levels was observed after SEMS insertion, which might explain the reason why different inflammation indexes were concluded from the ES (dNLR) and BTS (LMR) groups in our study.

Since 1970, a decreasing peripheral lymphocyte count has been recorded in advanced colon cancer\[[@B26]\], and the inflammation index has been investigated in several kinds of cancer, as it is cost-effective and convenient. The dysbiosis and outgrowth of intestinal microbial species, as a result of acute bowel obstruction and distention, triggers systemic inflammation, leading to the accumulation of neutrophils and monocytes that secrete cytokines and chemokines with the induction of reactive oxygen species (ROS) and reactive nitrogen intermediates (RNI), which might aggravate colonic injury and DNA damage\[[@B11]\]. OCC almost coexists with immunosuppression, which causes a deficiency in adaptive immunologic cells such as T lymphocytes and B lymphocytes, which play important roles in immune surveillance and pathogen depletion\[[@B27]\]. The mechanical stress of SEMS and chronic ablation to the colonic wall enhances local platelet adhesion and the mediation of tumor invasion into lymphovascular vessels\[[@B28]\], which was supported in the current study by a higher proportion of LVI in the BTS group. In this study, we compared different inflammation indexes, including the NLR, dNLR, PLR, LMR and SII, with the CEA level in terms of the predictive value for the prognosis between the ES and BTS groups. Finally, the dNLR was defined as the most efficient index in the ES group; a high dNLR (≥ 1.57) was closely related to low survival benefits, a high incidence of stoma construction, and postoperative pneumonia. Dissimilarly, the LMR was defined as the most efficient index in the BTS group; a high LMR (≥ 1.67) was closely related to low survival benefits and a high incidence of LVI and lymph node invasion.

The reason why different predictive models for the ES and BTS groups were observed in OCC is still unknown. This might be owing to the hypothesis that, as a result of bacterial outgrowth and translocation, OCC always has a severe systemic inflammatory response and immunological deficit, and for patients with a high surgical risk, a BTS *via* SEMS insertion is preferred. In this study, we found that the BTS group had more severe obstructive symptoms and a bigger tumor size than the ES group. Sufficient alleviation of bowel distention and preoperative nutritional support would improve systemic inflammation and enhance the immunological reaction in the BTS group. However, the mechanical stress of the metal stent might aggravate the local inflammatory response\[[@B29]-[@B31]\] and enhance tumor invasion. In our study, with the dramatic decrease of the systemic inflammatory response in the BTS group, the dNLR could not determine the benefit group for ES or BTS. Only the LMR could serve as an objective biomarker for the indication for OCC. A low LMR (\< 1.67) was correlated with a low incidence of death and tumor recurrence in the BTS group. Conversely, a high LMR (≥ 1.67) showed a high proportion of death and tumor recurrence in the BTS group, and was preferred for ES.

There were some limitations existing in this study. First, this was a retrospective study in a single center; thus, we will initiate a prospective, multicenter study to confirm our findings. Second, the sample size was not so large that more patients are needed in future research. Furthermore, this study just analyzed the ratio of immune cell populations in the peripheral blood, instead of systematic immune responses including the production of cytokines or expression of PD-1 or CTLA-4. More efforts should be made on the investigation of immune responses occurring in the systemic circulation or tumor.

In conclusion, this study suggests a similar survival and oncological benefits for BTS and ES in patients with OCC. Even though different inflammation indexes for prediction of the prognosis were observed between the ES and BTS groups, they could serve as effective biomarkers. The dNLR was closely related to the prognosis in the ES group, while the LMR was closely related to the prognosis in the BTS group. Specifically, as the potential benefit group, patients with a low LMR might be preferred for BTS *via* SEMS insertion.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Obstructive colorectal cancer (OCC) presenting with acute abdominal symptoms is always accompanied by severe complications, and the optimal strategy for patients with OCCs remains undetermined. Emergency surgery (ES) and self-expandable metal stents (SEMS) as a bridge to surgery (BTS) were the major treatments for OCCs, however, the indications remain debated. According to different status of immunology and nutrition, predictive factors for prognosis might be different between the two groups. Preoperative inflammation indexes might favor patient selection in terms of the prognosis of OCC.

Research motivation
-------------------

Weighing the waxes and wanes of ES and BTS, both acute and chronic inflammation responses should be accounted for the selection of optimal patients.

Research objectives
-------------------

This study was designed to build an inflammatory model for the surgical indications for ES and BTS in OCC.

Research methods
----------------

This was a retrospective study in which 128 patients who underwent surgery for OCC at the Department of Emergency Surgery of Fujian Medical University Union Hospital from January 2008 to October 2015 were included in this study. Patients were divided into an ES group and a BTS group according to the surgeon' advises and patients' selection. Inflammation indexes were fully evaluated in this study.

Research results
----------------

Comparable survival outcomes were observed between the ES and BTS groups. Receiver operating characteristic curve analysis showed dNLR as the optimal biomarker for the prediction of DFS in ES, by contrast, LMR was recommended for BTS with regard to OS and DFS. dNLR was related to stoma construction, postoperative pneumonia, and DFS in the ES group. LMR was closely related to lymph nodes invasion, OS, and DFS in the BTS group. LMR could differentiate OS between the ES and BTS groups. A low LMR (\< 1.67) was correlated with a low incidence of death and tumor recurrence in the BTS group.

Research conclusions
--------------------

As a supplement for the latest ESGE guidelines, the indications for the use of SEMSs in OCC might elaborate to patients with low preoperative LMR, who would benefit from BTS *via* SEMS insertion.
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